CONNECTA THERAPEUTICS
Contact information
- Drug development
- Drug discovery
- Genetic and rare diseases
- Central nervous system
CONNECTA Therapeutics is a clinical-stage biotechnology company committed to developing new treatments for Central Nervous System (CNS) disorders that lack therapeutic options, with the aim of improving the quality of life patients and their families.
CONNECTA Therapeutics is developing new molecules for a wide range of neurodevelopmental and neurodegenerative diseases. The most advanced program focuses on the development of an NCE, CTH120, currently in clinical trials for the treatment of Fragile X Syndrome, the leading cause of inherited functional intellectual diversity.
CONNECTA Therapeutics is interested in establishing strategic collaborations to accelerate the clinical development of its molecules, and to expand its pipeline through the discovery of new candidates and the extension of other CNS diseases.
Thus, the company is open to considering and exploring different collaboration modalities. Co-development and licensing-out formulas (upfront + milestone) are the most actively considered.